YUAN FANG

Counsel·Shanghai

YUAN FANG

Counsel·Shanghai

YUAN FANG

Counsel·Shanghai

PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading

MS. FANG SPECIALIZES IN CAPITAL MARKETS, INCLUDING PUBLIC OFFERING, M&A AND RESTRUCTURING, EQUITY INVESTMENT AND GENERAL CORPORATE MATTERS.

Education

Peking University, J.M.

Zhejiang University, B.A.

Professional Qualification

Admitted to practice in the PRC

Professional Background

Ms. Fang joined Fangda in 2019.

PROFILE

REPRESENTATIVE MATTERS AND CASES

  • Represented BeiGene, Ltd. in its A-share IPO on the STAR Market
  • Represented InnoCare Pharma Limited in its A-share IPO on the STAR Market
  • Acted as the sponsor and underwriter's counsel in China Resources Microelectronics Limited’s A-share IPO on the STAR Market
  • Represented Zoomlion Heavy Industry Science and Technology Co., Ltd. in its acquisition of the controlling stake in ShenZhen RoadRover Technology Co., Ltd.
  • Represented Shanghai Highly (Group) Co., Ltd. in its acquisition of the controlling stake in Marelli (Hong Kong) Holdings Co., Limited
  • Represented China Shipbuilding Industry Corporation in its acquisition of the controlling stake in CEC CoreCast Corporation Limited through negotiated share transfer
  • Represented ABB (China) Limited in its disposal of the controlling stake in its subsidiaries to Shanghai Guangdian Electric Group Co., Ltd. through material asset restructuring
  • Represented Ningbo Jifeng Auto Parts Co., Ltd. in its acquisition of the controlling stake in Grammer AG with cash and issuance of convertible bonds and A shares
  • Represented Beijing Highlander Digital Technology Co., Ltd. in its acquisition of the minority interests in its subsidiaries with issuance of A-shares
  • Represented China Marine Information Electronics Company Limited in its acquisition of the controlling stake in Beijing Great Wall Electronic Equipment Co., Ltd. through backdoor listing
  • Represented Ant Financial in its investment in Shanghai Golden Bridge InfoTech Co., Ltd.
  • Represented DCP Capital in its investment in Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Represented Alibaba in its investment in Shenzhen Aisidi Co., Ltd.

OTHER INFORMATION